BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 2, 2016--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Amar
Sawhney, Ph.D., President and Chief Executive Officer, will present at
two upcoming investor conferences:
-
Jefferies 2016 Healthcare Conference
Tuesday, June 7, 2016
at 8:00 a.m. Eastern Time
The Grand Hyatt Hotel, New York, NY
-
JMP Securities 2016 Life Sciences Conference
Wednesday,
June 22, 2016 at 10:30 a.m. Eastern Time
The St. Regis Hotel, New
York, NY
Live audio webcasts of the presentations can be accessed through the
Calendar of Events section of the Company's website at
investors.ocutx.com. Replays of the webcasts will be available on the
Company's website for two weeks following each presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix's lead product candidate,
DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot, is
in Phase 3 clinical development for post-surgical ocular inflammation
and pain and allergic conjunctivitis, and in Phase 2 clinical
development for dry eye disease. A New Drug Application (NDA) for the
post-operative ocular pain indication has been filed with FDA and has a
Prescription Drug User Fee Act (PDUFA) target action date of July 24,
2016. A third Phase 3 clinical trial is being conducted for
post-surgical ocular inflammation and pain. For glaucoma and ocular
hypertension, the Company has completed its End-of-Phase 2 review with
the FDA, and the first of two planned OTX-TP (sustained release
travoprost) Phase 3 clinical trials is expected to be initiated in the
third quarter of 2016. Ocular Therapeutix is also evaluating
sustained-release injectable anti-VEGF drug depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160602006202/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com
